Patients with Huntington’s disease, a fatal genetic illness that causes the breakdown of nerve cells in the brain, have up to 80 percent less cancer than the general population.
Northwestern Medicine scientists have discovered why Huntington’s is so toxic to cancer cells and harnessed it for a novel approach to treat cancer, a new study reports.
Huntington’s is caused by an over abundance of a certain type of repeating RNA sequences in one gene, huntingtin, present in every cell. The defect that causes the disease also is highly toxic to tumor cells. These repeating sequences — in the form of so-called small interfering RNAs — attack genes in the cell that are critical for survival. Nerve cells in the brain are vulnerable to this form of cell death, however, cancer cells appear to be much more susceptible.
“This molecule is a super assassin against all tumor cells,” said senior author Marcus Peter, the Tom D. Spies Professor of Cancer Metabolism at Northwestern University Feinberg School of Medicine. “We’ve never seen anything this powerful.”
Huntington’s disease deteriorates a person’s physical and mental abilities during their prime working years and has no cure.
The study will be published Feb. 12 in the journal EMBO Reports.
To test the super assassin molecule in a treatment situation, Peter collaborated with Dr. Shad Thaxton, associate professor of urology at Feinberg, to deliver the molecule in nanoparticles to mice with human ovarian cancer. The treatment significantly reduced the tumor growth with no toxicity to the mice, Peter said. Importantly, the tumors did not develop resistance to this form of cancer treatment.
Peter and Thaxton are now refining the delivery method to increase its efficacy in reaching the tumor. The other challenge for the scientists is figuring out how to stabilize the nanoparticles, so they can be stored.
First and co-corresponding author Andrea Murmann, research assistant professor in medicine at Feinberg, also used the molecule to treat human and mouse ovarian, breast, prostate, liver, brain, lung, skin and colon cancer cell lines. The molecule killed all cancer cells in both species.
The Huntington’s cancer weapon was discovered by Murmann, who had worked with Peter on earlier research that identified an ancient kill-switch present in all cells that destroys cancer.
“I thought maybe there is a situation where this kill switch is overactive in certain people, and where it could cause loss of tissues,” Murmann said. “These patients would not only have a disease with an RNA component, but they also had to have less cancer.”
She started searching for diseases that have a lower rate of cancer and had a suspected contribution of RNA to disease pathology. Huntington’s was the most prominent.
When she looked at the repeating sequences in huntingtin, the gene that causes the disease, she saw a similar composition to the earlier kill switch Peter had found. Both were rich in the C and G nucleotides (molecules that form the building blocks of DNA and RNA).
“Toxicity goes together with C and G richness,” Murmann said. “Those similarities triggered our curiosity.”
In the case of people who have Huntington’s, the gene huntingtin has too many repeating sequences of the triplet sequence CAG. The longer the repeating sequence, the earlier they will develop the disease.
“We believe a short-term treatment cancer therapy for a few weeks might be possible, where we could treat a patient to kill the cancer cells without causing the neurological issues that Huntington’s patients suffer from,” Peter said.
Peter also is co-leader of the Translational Research in Solid Tumors Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Huntington’s patients have a lifetime exposure to these toxic RNA sequences, but generally don’t develop symptoms of the disease until age 40, he noted.
Every child of a parent with Huntington’s has 50/50 chance of carrying the faulty gene. Today, there are approximately 30,000 symptomatic Americans and more than 200,000 at-risk of inheriting the disease.
Learn more: Huntington’s disease provides new cancer weapon
The Latest on: Cancer therapy
via Google News
The Latest on: Cancer therapy
- Independent Discovery Validates Noxopharm’s DARRT Cancer Therapyon December 3, 2020 at 7:18 am
Noxopharm announces a discovery by Cornell Medical College published in Nature Immunology validating the novel DARRT anti-cancer treatment of Veyonda® ...
- ‘Stealth bomber’ virus could fight metastatic canceron December 3, 2020 at 7:00 am
A new "stealth bomber" cancer-killing virus is able to sneak through the blood without arousing a massive inflammatory reaction, researchers say.
- Why This Breast Cancer Warrior Urges Others With The Disease to Get Genetic Testingon December 3, 2020 at 6:00 am
It’s just one more piece of the puzzle that your doctor can use to decide what the best treatment should be for you.” ...
- Prostate cancer: Persistent back pain could be a warning sign of the diseaseon December 3, 2020 at 2:45 am
PROSTATE cancer may spread to the bones; this is known as secondary cancer. Persistent back pain could be a warning sign of the disease - what are the other symptoms?
- Stomach Cancer Treatment Market Size 2020 Segmentation, Future Demands, Top Countries Data, Business Growth Forecast to 2026on December 3, 2020 at 12:09 am
Final Report will add the analysis of the impact of COVID-19 on this industry." This “Stomach Cancer Treatment ...
- Q&A: Y-90 therapy offers many benefits in treatment of liver canceron December 2, 2020 at 12:46 pm
My father has had chronic liver disease. Recently, he was diagnosed with liver cancer. His doctor mentioned Y-90 as one treatment option. What is Y-90, and is it safe?
- Breast Cancer Therapy Market measure Analysis, Revenue, Price, Market measure Share, Growth Rate, Forecast to 2026on December 2, 2020 at 9:38 am
The Global Breast Cancer Therapy Market is anticipated to reach USD 29.6 Billion by 2026 according to a new research. In 2017, the targeted therapy segment dominated the global market, in terms of ...
- Clinical Challenges: Lung Cancer and COVID-19on December 1, 2020 at 10:10 am
There is no question that lung cancer patients are an extremely vulnerable population when it comes to COVID-19. For example, in a study assessing the impact of COVID-19 on cancer patients in the ...
- Finnish researchers say AI tool can help optimize cancer combination therapyon December 1, 2020 at 10:05 am
Researchers in Finland have developed a machine-learning tool that accurately predicts how different cancer drugs kill disease cells, according to a paper published Tuesday by Nature Communications.
- Second opinion changed breast cancer treatment, preserved fertilityon December 1, 2020 at 8:48 am
The University of Kansas Cancer Center is one of 71 National Cancer Institute-designated cancer centers nationwide where patients have a 25% greater chance of survival than those at other cancer ...
via Bing News